Jérôme Varvat

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Prevalence of Poststroke Neurocognitive Disorders Using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit

Mélanie Barbay, H. Taillia, Claudine Nédélec-Ciceri et al. · Stroke · 2018 · 97 citations

Medicine, Neurology, Neuroscience +17

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke

Pierre Amarenco, Jong S. Kim, Julien Labreuche et al. · Stroke · 2020 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Intracranial Hemorrhage in the TST Trial

Pierre Amarenco, Julien Labreuche, Maurice Giroud et al. · Stroke · 2021 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Differentiating between Alzheimer’s Disease and Vascular Cognitive Impairment: Is the “Memory Versus Executive Function” Contrast Still Relevant?

Daniela Andriuta, Martine Roussel, Mélanie Barbay et al. · Journal of Alzheimer s Disease · 2018 · 22 citations · Full text

Medicine, Neurology, Neuroscience +17